You are here:

Harvest One Cannabis Inc. – Favourable Results from Phase 2 – CNW

PTL’s Phase 2 open label clinical trial is aimed at measuring safety and efficacy of Satipharm CBD capsules for reducing seizure frequency in children with refractory, or treatment-resistant, epilepsy.

Satipharm CBD capsules are a proprietary oral formulation developed using the Gelpell-CBD™ product technology.

Satipharm CBD capsules reduced monthly seizure frequency in the treatment-resistant children when added to current medications. The treatment was generally well tolerated, with a safety profile consistent with prior experience.

Promising evidence of efficacy has been reported. In 6 patients a reduction of 59-91% in mean monthly seizure frequency was observed following 12 weeks of treatment.

The median reduction was -79.5% in the 12-week treatment period compared to the 4-week observation period.

Importantly, the initial results received to date indicate that Satipharm’s capsules significantly reduce monthly seizure frequency when added to current medications, with strong evidence of efficacy reported.